Pharvaris NV Stock Quote PHVS - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

20.35

Bid

8.36

Ask

24.59

Volume

33,049

19.53 Day's Range 21.70

8.20 52 Week Range 33.00

Market Cap

830.746M

Previous Close

21.71

Open

21.70

Last Trade

1000

20.35

Last Trade Time

Financial Volume

$ 683,571

VWAP

20.6835

Average Volume (3m)

71,203

Shares Outstanding

40,822,916

Dividend Yield

PE Ratio

-8.24

Earnings Per Share (EPS)

-2.47

Revenue

Net Profit

-100.88M

Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.pharvaris.com

Headquarters

Leiden, South Holland, Nld

Founded

1970

Pharvaris NV is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PHVS. The last closing price for Pharvaris NV was $21.71. Over the last year, Pharvaris NV shares have traded in a share price range of $ 8.20 to $ 33.00.

Pharvaris NV currently has 40,822,916 shares outstanding. The market capitalization of Pharvaris NV is $830.75 million. Pharvaris NV has a price to earnings ratio (PE ratio) of -8.24.

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

The company announced the initiation of RAPIDe-3, the Phase 3 clinical trial evaluating the efficacy and safety of deucrictibant immediate-release capsule (PHVS416) for the treatment of HAE...

Form 144 - Report of proposed sale of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.44	-2.1164021164	20.79	24.11	19.53	36355	21.59484772	CS
4	2.3	12.7423822715	18.05	25.5	17.57	58682	22.23384839	CS
12	-7.82	-27.760028399	28.17	28.395	17.57	71203	22.85181934	CS
26	4.75	30.4487179487	15.6	33	15	123359	25.26452203	CS
52	11.69	134.988452656	8.66	33	8.2	85039	22.97579294	CS
156	-1.25	-5.78703703704	21.6	33	1.77	216835	12.16057926	CS
260	-4.65	-18.6	25	42.86	1.77	207613	12.93798335	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
DUOFangDD Network Group Ltd	$ 1.65 (313.74%)	104.68M
FLJFLJ Group Limited	$ 1.54 (220.90%)	57.28M
JFBRJeffs Brands Ltd	$ 0.6276 (102.45%)	37.97M
IPWiPower Inc	$ 2.89 (97.95%)	11.05M
CETXCemtrex Inc	$ 0.4851 (48.58%)	21.23M
BSFCBlue Star Foods Corporation	$ 0.0757 (-45.26%)	60.09M
SINTSiNtx Technologies Inc	$ 0.084602 (-39.57%)	156.35M
FFIEFaraday Future Intelligent Electric Inc	$ 1.0189 (-38.25%)	1.31B
HSCSHeart Test Laboratories Inc	$ 7.00 (-38.11%)	348.9k
AMPGAmplitech Group Inc	$ 1.46 (-32.09%)	613.31k
CRKNCrown Electrokinetics Corporation	$ 0.171 (-28.75%)	1.74B
FFIEFaraday Future Intelligent Electric Inc	$ 1.0189 (-38.25%)	1.31B
GWAVGreenwave Technology Solutions Inc	$ 0.1541 (4.05%)	1.16B
AKANAkanda Corporation	$ 0.1726 (30.26%)	566.51M
PEGYPineapple Energy Inc	$ 0.1053 (-28.85%)	219.25M